Ridgewood Investments’s Iovance Biotherapeutics IOVA Stock Holding History

Ridgewood Investments’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-300	Closed	-$516	–	435
2025 Q2	$516	Hold	300	–	–	﹤0.01%	697
2025 Q1	$999	Hold	300	–	–	﹤0.01%	636
2024 Q4	$2.22K	Hold	300	–	–	﹤0.01%	643
2024 Q3	$2.82K	Hold	300	–	–	﹤0.01%	640
2024 Q2	$2.41K	Buy	+300	New	+$3.21K	﹤0.01%	656

Other funds holding IOVA

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ridgewood Investments's IOVA Position: Q3 2025 in Review

Ridgewood Investments sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 300 shares — an estimated $516 sold.

Ridgewood Investments first reported a position in IOVA in Q2 2024 and held it in 5 quarters. The position peaked at $2.82K in Q3 2024. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

Ridgewood Investments reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
Ridgewood Investments sold 300 Iovance Biotherapeutics shares in Q3 2025, an estimated $516.
Ridgewood Investments first reported a position in Iovance Biotherapeutics in Q2 2024 and held it in 5 quarters.
Ridgewood Investments's Iovance Biotherapeutics position peaked at $2.82K in Q3 2024.
253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Ridgewood Investments's 13F filing for Q3 2025, filed 30 Oct 2025.